How Analysts Feel About GW Pharmaceuticals plc (GWPH) After Today’s Significant Increase?

December 7, 2017 - By Darrin Black

The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) is a huge mover today! The stock increased 7.73% or $8.97 during the last trading session, reaching $124.97. About 1.22M shares traded or 223.85% up from the average. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 31.90% since December 7, 2016 and is uptrending. It has outperformed by 15.20% the S&P500.
The move comes after 9 months positive chart setup for the $3.17 billion company. It was reported on Dec, 7 by Barchart.com. We have $131.22 PT which if reached, will make NASDAQ:GWPH worth $158.50 million more.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

Among 13 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. GW Pharmaceuticals had 22 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) earned “Buy” rating by Maxim Group on Monday, August 7. The firm earned “Buy” rating on Monday, March 14 by Roth Capital. Piper Jaffray maintained GW Pharmaceuticals plc (NASDAQ:GWPH) rating on Thursday, August 3. Piper Jaffray has “Buy” rating and $14700 target. The stock has “Buy” rating by Cantor Fitzgerald on Friday, June 3. On Monday, September 26 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Morgan Stanley initiated GW Pharmaceuticals plc (NASDAQ:GWPH) on Thursday, August 13 with “Overweight” rating. As per Friday, August 26, the company rating was upgraded by Numis Securities. On Monday, November 30 the stock rating was initiated by TH Capital with “Buy”. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given on Monday, September 25 by Cowen & Co. The stock has “Buy” rating by Cantor Fitzgerald on Monday, December 5.

More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Investorplace.com which released: “Get Long GW Pharmaceuticals PLC- ADR (GWPH) Stock for Free” on July 12, 2017, also Investorplace.com with their article: “Get Long GW Pharmaceuticals PLC- ADR for Free” published on December 04, 2017, Investorplace.com published: “GW Pharmaceuticals PLC- ADR (GWPH) Stock Is High-Risk, High Reward” on August 18, 2017. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Investorplace.com and their article: “GW Pharmaceuticals PLC- ADR (GWPH) Stock Is Just Getting Started” published on December 06, 2016 as well as Benzinga.com‘s news article titled: “Is GW Pharma Now The Future Of Cannabis-Based Drugs?” with publication date: August 08, 2017.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company has market cap of $3.17 billion. It operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development. It currently has negative earnings. The firm markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.